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1. Introduction 
Chronic kidney disease (CKD) affects millions of people worldwide, with high incidence 
and prevalence and increasing costs. Anemia, a common observation in CKD, can develop 
in the early phases of the disease and contributes to a poor quality of life (Eknoyan et al., 
2004). 
Anemia in patients with CKD is due to many factors. Erythropoiesis and iron homeostasis 
are impaired as a result of a complex chain of events, including the relative deficiency of 
erythropoietin, chronic inflammation, blood loss, decreased iron absorption and utilization, 
exogenous iron and erythropoietin acquisition via biologically unregulated mechanisms 
(blood transfusions and medicinal erythropoietin and iron administration) (Weiss, 2009; 
Guidi & Santonastaso, 2010; Lankhorst & Wish, 2010). 
The advent of erythropoiesis stimulating agents (ESA) and various intravenous iron 
preparations has resulted in a much more effective management of anemia of CKD, 
allowing us to maintain hemoglobin levels in certain desired ranges and to effectively treat 
iron deficiency. Among the emerging challenges are the risks associated with administering 
high ESA and iron doses, leading to elevated hemoglobin levels and iron overload (Zager et 
al., 2002). 
Recombinant human erythropoietin (rHuEpo) has been available for treatment of renal 
disease anemia since 1989. However, rHuEpo therapy results in iron deficiency due to 
insufficient iron stores for the accelerated erythropoiesis. Iron deficiency is the main cause of 
suboptimal response to erythropoietin in dialysis patients (Cavill & Macdougall, 1993). 
Maintenance iron supplementation is required to successfully treat anemia; intravenous iron 
compounds are used to treat dialysis patients who become iron deficient. 
Monitoring erythropoietin treated patients’ iron status is important to detect iron deficiency 
and avoid the adverse effects of iron medication. The assessment of iron requirements and 
monitoring of therapy require accurate markers. New alternative markers for iron status 
that may be useful when serum ferritin and transferrin saturation are insufficient. These 
newer tests include reticulocyte hemoglobin content, percentage of hypochromic red cells 
www.intechopen.com
 Chronic Kidney Disease 
 
226 
and soluble transferrin receptor, all of which have shown some promise in recent studies 
(Goodnough et al., 2010). 
The percentages of hypochromic red cells (%Hypo) and reticulocyte hemoglobin content 
(CHr) are reported by the Siemens analyzers (Siemens Medical Solutions Diagnostics, 
Tarrytown NY, USA). 
Two other parameters correlate to %Hypo and CHr, erythrocyte hemoglobin equivalent 
(RBC-He) and reticulocyte hemoglobin equivalent (Ret-He), reported by the Sysmex XE-
2100 analyzer (Sysmex Corporation, Kobe, Japan); percentages of hypochromic red cells (% 
Hypo He) are now available on the Sysmex analyzer XE 5000 (Sysmex Corporation, Kobe, 
Japan. 
Beckman Coulter (Beckman Coulter Inc., Miami, Fl, USA) has introduced on the LH series 
analysers a new parameter, low hemoglobin density (LHD%), related to the iron availability 
for erythropoiesis in the previous weeks; derived from mean cell hemoglobin concentration 
(MCHC). In this chapter the potential clinical utility of this parameter in the assessment of 
iron status in CKD patients is discussed.  
1.1 Iron homeostasis 
The normal Western diet contains 15–20 mg iron in Hem (10%) and non-Hem (ionic, 90%) 
forms. Only 1–2 mg of iron is absorbed and lost every day. Importantly, the total amount of 
iron in the body can be regulated only by absorption, whereas iron loss occurs only passively 
from sloughing of skin and mucosal cells as well as from blood loss. Iron absorption is 
balanced against iron loss so daily iron absorption may increase in response to increased iron 
demand (eg, growth, pregnancy or blood loss) (Conrad et al., 2002; (Miret et al., 2003). 
Nearly all absorption of dietary iron occurs in the duodenum. Several steps are involved, 
including the reduction of iron to a ferrous state, apical uptake, intracellular storage or 
transcellular trafficking, and basolateral release. Molecular participants in each of these 
processes have been identified.  
The non-Hem iron mainly exists in the Fe3+ state. The ferric iron is reduced to ferrous iron 
before it is transported across the intestinal epithelium. The reduction of iron from the ferric 
to the ferrous state occurs at the enterocyte brush border by means of a duodenal ferric 
reductase (Dcytb). Once the insoluble Fe3+ is converted to Fe2+. Ferrous iron is then 
transported across the apical plasma membrane of the enterocyte by divalent metal 
transporter 1 (DMT1) DMT1 is expressed at the duodenal brush border where it controls 
uptake of dietary iron, and also traffics other metal ions such as zinc, copper and cobalt by a 
proton-coupled mechanism (Conrad et al., 2002). 
Iron taken up by the enterocyte may be stored intracellularly as ferritin (and excreted in the 
feces when the senescent enterocyte is sloughed) or transferred across the basolateral 
membrane to the plasma. This iron is transferred out of the enterocyte by the basolateral 
transporter ferroportin; this process is facilitated by the ferroxidase activity of the 
ceruloplasmin homologue hephaestin (Fleming et al., 2005). 
There are no substantial physiologic mechanisms that regulate iron loss. Accordingly, iron 
homeostasis is dependent on regulatory feedback between body iron needs and intestinal 
iron absorption. 
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Iron stores, erythropoietic activity, hemoglobin, oxygen content, and inflammation 
modulates the dietary iron absorption (Nemeth et al., 2004).  
Essentially all circulating plasma iron normally is bound to transferrin. The liver synthesizes 
transferrin and secretes it into the plasma. The chelation of ferric iron serves three purposes: 
it renders iron soluble under physiologic conditions, it prevents iron-mediated free radical 
toxicity, and it facilitates transport into cells. Transferrin is the most important physiological 
source of iron for red cells (Ponka, 1998). 
Although transferrin was characterized fifty years ago, its receptor eluded investigators 
until the early 1980s.  
The molecule is a transmembrane homodimer linked by disulfide bonds. This disulfide-
linked homodimer has subunits containing 760 amino acids each. Oligosaccharides account 
for about 5% of the 90 kDa subunit molecular mass. A broad body of literature now 
supports the concept that the iron-transferrin complex is internalized by receptor-mediated 
endocytosis. (Beaumont et al., 2009). 
Most of the body iron is associated to hemoglobin in circulating erythrocytes. Erythropoiesis 
is a very active process that takes place in the bone marrow and leads to the daily 
production of 200 billion new erythrocytes to compensate for the destruction of senescent 
red cells by tissue macrophages. The control of erythropoiesis depends mostly on 
erythropoietin production by the kidney and on the availability of iron.  
Macrophages play a central role in the organism as they recycle iron after phagocytosis of 
senescent erythrocytes. This mechanism mainly occurs in the spleen and bone marrow and 
to a lesser extent in the Küpffer cells of the liver.  
During aging, erythrocytes accumulate multiple modifications (cell shrinkage, 
externalization of phosphatidyl-serine, peroxydation of the membrane). The fixation and 
ingestion of red cells by macrophages are triggered by cellular receptor-mediated 
phagocytosis (through recognition of externalized phosphatidyl-serine or neoantigens of 
senescence) (Lang et al., 2005). 
Iron can be stored in the macrophages associated to ferritin or hemosiderin or exported to 
the plasma. Iron export from macrophages to transferrin is accomplished by ferroportin, the 
same iron-export protein as expressed in the duodenal enterocyte, and reoxydized by 
ceruloplasmin (Knutson et al., 2005). 
Metabolically inactive iron, is stored in ferritin and hemosiderin. Normally, 95% of the 
stored iron in liver tissue is found in hepatocytes as ferritin. The level of serum ferritin 
parallels the concentration of storage iron within the body, regardless of the cell type in 
which it is stored. 
The control of iron homeostasis acts at both the cellular and the systemic level and involves 
a complex system of different cell types, transporters, and signals. To maintain systemic iron 
homeostasis, communication between cells that absorb iron from the diet (duodenal 
enterocytes), consume iron (mainly erythroid precursors), and store iron (hepatocytes and 
tissue macrophages) must be tightly regulated (Swinkels et al., 2006). 
In the last 10 years, understanding of the regulation of iron homeostasis has changed 
substantially. A small peptide hormone, hepcidin, emerged as the central regulator of iron 
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absorption, plasma iron levels, and iron distribution. Hepcidin is secreted by mainly by 
hepatocytes, and to a lesser extent by macrophages and adipocytes. The hormone inhibits 
iron flows into plasma from macrophages involved in recycling of senescent erythrocytes, 
duodenal enterocytes engaged in the absorption of dietary iron, and hepatocytes that store 
iron.( Ganz & Nemeth, 2009). 
The human hepcidin gene is located on chromosome 19q13.1, encodes a precursor protein of 
84 amino acids. During its export from the cytoplasm, this full-length pre-prohepcidin 
undergoes enzymatic cleavage, resulting in a 64 amino acids prohepcidin. Next, the 39 
amino acids pro-region peptide is probably post-translationally removed, renders bioactive 
hepcidin-25. In human urine also are identified hepcidin-22 and hepcidin-20, which are N-
terminally truncated iso-forms of hepcidin-25 (Kemna et al., 2008). 
Hepcidin expression is controlled by various stimuli: iron, inflammation, erythropoiesis, 
and hypoxia. iron and inflammation induce hepcidin production, while iron deficiency, 
hypoxia, and stimulation of erythropoiesis completely inhibit its production. Hepcidin is 
secreted into the circulation, where it down-regulates the ferroportin-mediated release of 
iron from enterocytes, macrophages and hepatocytes and is the key for the regulation of 
systemic iron homeostasis (Fleming et al., 2005), reduces the quantity of circulating iron by 
limiting the egress of the metal from both intestinal and macrophage cells; the cellular 
process by which hepcidin acts, through its binding to ferroportin, thereby inducing 
internalization and subsequent degradation of the exporter (Bergamaschi & Villani., 2009). 
In the intestine, delivery of dietary iron to plasma transferrin is inhibited by increasing 
concentrations of hepcidin, and iron is subsequently removed from the body, through the 
elimination of enterocytes (desquamation process). In macrophages, degradation of 
ferroportin by hepcidin results in the trapping of iron inside the cells, thereby limiting the 
acquisition of iron by erythroid cells (Nemeth et al., 2004).  
Figure 1 shows and summarizes the information contained on the previous section. 
1.2 Anemia in CKD 
Anemia of chronic disease (ACD), the most frequent anemia among hospitalized patients, 
occurs in chronic inflammatory disorders, such as chronic infections, cancer and 
autoimmune diseases; is a hypoproliferative anemia, defined by low plasma iron 
concentrations in the presence of high reticuloendotelial iron stores. Cytokines are 
implicated in the ACD increasing iron sequestration in the reticuloendothelial system (Weiss 
& Goodnough, 2005), results in hyposideremia. This results in limited availability of iron for 
erythroid progenitor cells and iron restricted erythropoiesis. 
A particular case of ACD is represented by anemia of chronic kidney disease (CKD). 
CKD is becoming a major public health problem worldwide; the incidence and prevalence 
of this disease is increasing and the costs of treatment lead to a large burden for the health 
care systems, particularly in developing countries (Guidi & Santonastaso, 2010).  
The severity of kidney disease is classified into five stages according to the glomerular 
filtration rate (GFR). It is estimated that approximately half of the patients in stage 3 CKD 
(GFR: 30–59 mL/min/1.73 m2) are anemic (Eknoyan et al., 2004). 
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Fig. 1. Iron is absorbed from the diet by duodenal enterocytes and then bound to plasma 
transferrin (Tf). Fe-Tf is distributed to the bone marrow for erythropoiesis. At the end of 
their lifespan, senescent erythrocytes are phagocytosed by tissue macrophages and heme 
iron is recycled back to plasma transferrin.  
Hepcidin regulates the systemic iron homeostasis; synthesized by the liver is secreted into 
the circulation, where it down-regulates the ferroportin-mediated release of iron from 
enterocytes, macrophages, and hepatocytes.  
Swinkels, D. W. et al. Clin Chem 2006;52:950-968. 
Anemia, a common observation in CKD, can develop in the early phases of the disease is 
associated to poor outcomes and contributes to a reduced quality of life, with symptoms 
including dyspnea, headache, light-headedness, and fatigue. Anemia in patients with CKD 
is due to many factors. The most well-known cause is inadequate production of 
erythropoietin. As renal failure progresses, the contribution of erythropoietin deficiency to 
anemia increases (Lankhorst & Wish, 2010).  
Other causes which lead to impaired erythropoiesis contribute to anemia include diversion 
of iron traffic, diminished erythropoiesis, blunted response to erythropoietin, 
erythrophagocytosis, reduced proliferative activity of erythroid precursors in bone marrow, 
reduced survival of red cells, the decreased iron availability lead to impaired erythropoiesis 
(Weiss, 2009). 
Absolute iron deficiency is defined as a decreased total iron body content. Iron deficiency 
anemia (IDA) occurs when iron deficiency is sufficiently severe to diminish erythropoiesis 
and cause the development of anemia. Functional iron deficiency describes a state where the 
total iron content of the body is normal or even elevated, but the iron is “locked away” and 
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unavailable for the production of red blood cells. This condition is observed mainly in 
patients with chronic renal failure who are on hemodialysis. 
Functional iron deficiency is defined as an imbalance between the iron needs for 
erythropoiesis and the iron supply, with the latter not maintained at sufficient rate for 
adequate hemoglobinization of reticulocytes and mature erythrocytes (Cavil & Macdougal, 
1993).  
In iron deficiency anemia (IDA) iron supply depends on the quantity of iron storage in the 
body, while in functional iron deficiency (iron restricted erythropoiesis) supply depends on 
the rate of mobilization of iron from the stores. The diagnosis of iron deficiency or functional 
iron deficiency is particularly challenging in patients with acute or chronic inflammatory 
conditions because most of the biochemical markers for iron metabolism are affected by 
acute phase reaction. This is the case of the anemia of chronic disease (ACD) and the anemia 
associated to chronic renal failure (CKD).  
Recombinant human erythropoietin (rHuEpo) has been available for treatment of renal 
disease anemia since 1989 (Esbach et al., 1989). However, rHuEpo therapy results in 
functional iron deficiency due to insufficient iron stores for the accelerated erythropoiesis. 
Iron deficiency is the main cause of suboptimal response to erythropoietin in dialysis 
patients. Maintenance iron supplementation is required to successfully treat anemia. Long 
term orally administered iron therapy is limited by noncompliance, gastrointestinal side 
effects, insufficient absorption and drug interaction; intravenous iron compounds are used 
to treat dialysis patients who become iron deficient (Macdougal, 1995). 
Monitoring erythropoietin treated patients’ iron status is important to detect iron deficiency 
and avoid the adverse effects of iron medication (Sunder-Plassmann & Hörl, 1997; 
Kletzmayr et al., 2002; Zager et al., 2002). 
Biochemical indicators of iron metabolism (iron levels, transferrin, transferrin saturation, 
ferritin) although widely used, may be influenced by the acute phase response, which 
complicates clinical interpretation of the test results. Serum ferritin, an indicator of iron 
storage but not of iron supply, is an acute phase reactant and its levels are affected by 
inflammation. Because cytokines are commonly increased in CKD, serum ferritin levels 
might not reflect true iron stores (Mast, 2001; Coyne, 2006).  
Transferrin is a negative acute phase reactant, rendering the calculation of transferrin 
saturation unreliable in this case. Transferrin fluctuates due to the diurnal variation of 
serum iron and is affected by nutritional status, leading to a lack of sensitivity and 
specificity in assessing iron’s availability (Fishbane et al., 1996). For these reasons, an iron 
deficient erythropoietic response to rHuEpo may occur despite normal serum ferritin and 
transferrin values.  
1.2.1 Guidelines for diagnosis of anemia 
After considerable review of the literature, Kidney Disease Outcomes Quality Initiative 
(K/DOQI) anemia work groups in 1997, 2001, and 2006 decided that the serum ferritin and the 
transferrin saturation (TSAT) should be the primary tools for assessing iron management in 
patients with anemia and chronic kidney disease, including end- stage renal disease. For 
patients with chronic kidney disease, absolute iron deficiency may be diagnosed when TSAT is 
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< 20% and serum ferritin is < 100 ng/mL. Functional iron deficiency may be more difficult to 
diagnose since iron status parameters may indicate adequate iron stores. There are different 
criteria in defining functional iron deficiency, one of them is published by the Kidney Disease 
Outcomes Quality Initiative- K/DOQI (Eknoyan et al. 2001). 
The serum ferritin reflects storage iron, and absolute iron deficiency, according to the 
K/DOQI guidelines, correlates with serum ferritin <100 ng/mL. Absolute iron deficiency, 
the iron deficiency that is characterized by low or absent bone marrow staining for iron, is to 
be distinguished from functional or relative iron deficiency, which is defined as a response 
to intravenous iron with an increase in hemoglobin (Hb) or a decrease in erythropoiesis-
stimulating agent requirement. 
In 2004, European Best Practice Guidelines suggested an Hb target of 110 g/L (Locatelli et 
al., 2004); values of >140 g/L were considered undesirable in general, and the limit for 
patients with cardiovascular disease was set at 120 g/dL. Caution of not exceeding the value 
of Hb concentrations 120 g/L was recommended to be given also for patients with diabetes, 
especially if they had concurrent peripheral vascular disease.  
Assessment of anemia should include the laboratory measurement of the following 
parameters: 
 Hb concentration, to assess the degree of anemia 
 Red blood cell indices (mean cell volume MCV, mean cell hemoglobin MCH), to assess 
the type of anemia 
 absolute reticulocyte count , to assess erythropoietic activity  
 plasma ferritin concentration, to assess iron stores 
 To assess iron available for erythropoiesis  
 percentage of hypochromic red cells  
 plasma transferrin Saturation  
 reticulocyte hemoglobin content 
 Plasma C reactive protein, to assess inflammation  
1.2.2 New parameters for the diagnosis of anemia 
The question regarding anemia therapy in those patients is which are the best parameters to 
assess the iron available for erythropoiesis. New laboratory parameters are reported by 
different manufacturers as potential tools for anemia and iron restricted erythropoiesis 
diagnosis. These tests include reticulocyte hemoglobin content, percentage of hypochromic 
red cells and soluble transferrin receptor (Wish, 2006; Goodnough et al., 2010). 
Serum transferrin receptor (sTfR) is a useful test for this purpose because it is not affected by 
inflammation so is a reliable marker of iron deficiency in mixed situations (Punnonen et al., 
1997; Beguin, 2003; Skikne, 2008). 
The sTfR test is based on the fact that erythroblasts in the bone marrow will increase the 
presentation of membrane transferrin receptor in the setting of iron deficiency. If a patient is 
not receiving sufficient iron and erythropoiesis is being stimulated by an ESA, then increased 
transferrin receptors will become expressed on the erythroblasts, some of which come off and 
will be detectable in the circulation. The sTfR correlates with this membrane expression of the 
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transferrin receptor and also tends to be elevated in the presence of increased erythroid 
activity. It does seem to be a reasonable index of erythropoietic activity (Chiang et al., 2002; 
Tarng & Huang, 2002) and reflects the effect of stimulating bone marrow red cells production, 
before an increase in reticulocytes is noted and well before the Hb rises; therefore an increase 
in the sTfR may be the first detectable measure. It is not affected by inflammation (Beerenhout 
et al., 2002) and this reason would make sTfR a more reliable test than serum ferritin. 
Direct consequence of an imbalance between the erythroid marrow iron requirements and 
the actual supply is a reduction of red cell hemoglobin content, which causes hypochromic 
mature red cells and reticulocytes. Interest has been generated in the use of erythrocyte and 
reticulocyte parameters, available on the modern analysers based on flow cytometry 
technology. 
The modern hematological parameters contribute to the advanced study of the anemia and 
depend on the technology employed; the debate about other parameters with the same 
clinical meaning and potential utility as reticulocyte hemoglobin content and percentage of 
hypochromic red cells is open. 
1.3 Technology at a glance 
The Hemogram is one of the more required tests by the clinicians; the analysis nowadays is 
totally automated and the correct interpretation of the results requires to unite the knowledge 
about the characteristics of the equipment and the clinical meaning of the results. The 
suppliers contribute innovations, providing new parameters that can help the clinicians to 
make a diagnosis in a fast, cheap and useful manner (Buttarello & Plebani, 2008). 
The professionals of the Clinical Laboratory must obtain the maximum yield of the new 
technologies obtaining as much information as possible.  
Automated blood cell counters have changed substantially during the last 20 years. 
Technological progress has meant that in recent years modern analyzers, fully automated, 
have been available. These analyzers report new parameters that provide further 
information from the traditional count; this information must be evaluated to prove the 
potential clinical utility in different clinical situations. 
When a state of iron deficiency proceeds red blood cells are continuously produced in the 
bone marrow and as the iron stores progressively decrease, mean cell volume (MCV), mean 
cell hemoglobin (MCH) and red blood cell count (RBC) count tend to decline. In iron 
deficient erythropoiesis, synthesis of hemoglobin (Hb) molecules is severely impaired 
leading to the production of erythrocytes with low Hb concentration (hypochromic cells). 
Because of their long life span of approximately 3 months, several cohorts of normochromic 
and increasingly hypochromic red cells coexist in the peripheral blood leading to 
anisocytosis; red cell distribution width (RDW) reflects the variation of size of the red cells. 
Flow cytometry provides information about individual cell characteristics. This is in contrast 
to previous measurements of MCV, MCH, and MCHC which only calculate mean indices 
for the total red cell population.  
MCV is the mean of the volumes of all erythrocytes; RDW refers to the variety of volumes 
present in the red cell population, so the whole picture is clear and the contribution of 
marginal sized subpopulations to the calculated mean value can be assessed. 
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This is not the case for MHC. MCH is calculated from red blood cell count and hemoglobin 
and represents the average; the percentage subsets of erythrocytes can give complementary 
information of the contribution of cell with extreme values (hypochromic and hyperchromic 
cells) to the mean values, reflecting the fluctuations of iron availability to the erythron in the 
previous weeks. 
Modern counters provide information about the reticulocyte counts but also about the 
characteristics of these cells (size or hemoglobin content) related to the quality of the 
erythropoiesis. 
Nevertheless, each Company applies the technology in a different way in the analyzers, with 
different algorithms to translate the electronic signals to graphs and numerical values. For this 
reason these new parameters are exclusive of each manufacturer and they are patented. 
1.3.1 Siemens 
On last decades, several new red blood cell and reticulocyte parameters have been reported 
having utilities in detection of iron deficiency and functional iron deficiency. Two of these 
parameters are hypochromic red cells (referred to as %Hypo) and CHr (reticulocyte 
hemoglobin content) reported by the Siemens ADVIA 120 hematology analyzer (Thomas & 
Thomas, 2002). 
Reticulocyte hemoglobin content (CHr) and the percentage of hypochromic red blood cells 
(%Hypo) reflect iron availability and are reliable markers of functional iron deficiency 
(Cullen et al., 1999). 
CHr is defined by the formula (CHr = MCVr X CHCMr), wherein MCVr is the mean 
reticulocyte cell volume and CHCMr is the mean hemoglobin concentration of reticulocytes, 
which is obtained by an optical cell-by-cell hemoglobin measurement. 
Reticulocytes are immature red blood cells with a life span of only 1 to 2 days. When these are 
first released from the bone marrow, measurement of their hemoglobin content can provide 
the amount of iron immediately available for erythropoiesis. A less than normal hemoglobin 
content in these reticulocytes is an indication of inadequate iron supply relative to demand. 
The amount of hemoglobin in these reticulocytes also corresponds to the amount of 
hemoglobin in mature red blood cells. CHr has been evaluated recently in numerous studies 
as a test for iron deficiency and functional iron deficiency and has been found to be highly 
sensitive and specific. However, exact threshold values have not been established, as the 
threshold values vary (28-30 pg), depending on the laboratory and instrument used. 
The measurement of CHr is a direct assessment of the incorporation of iron into erythrocyte 
hemoglobin and thus an estimate of the recent functional availability of iron into the 
erythron; due to the life span of the reticulocytes CHr is a sensitive indicator of iron 
deficient erythropoiesis (Fishbane et al., 1997; Mast et al., 2002; Brugnara 2003). 
Epoetin is effective in stimulating production, of red blood cells, but without an adequate 
iron supply to bind to heme, the red blood cells will be hypochromic, i.e., low in hemoglobin 
content. Thus, in states of iron deficiency, a significant percentage of red blood cells leaving 
the bone marrow will have a low hemoglobin content. By measuring the percentage of red 
blood cells with hemoglobin concentration <280 g/L, iron deficiency can be detected. 
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Hypochromic red cells percentages have been correlated with iron deficiency. %Hypo is 
reported by Siemens Advia 120 hematology analyzer based on the optical cell-by-cell 
hemoglobin measurement (Figures 2 and 3). 
 
Fig. 2. RBC Scatter Cytogram. 
1. Low-angle light scatter (2° to 3°) 
2. High-angle light scatter (5° to 15°) 
3. Mie map containing RBCs 
4. Platelets detected in RBC method 
The RBC Scatter cytogram is the graphical representation of two light-scatter measurements: 
the high-angle light scatter (5° to 15°) is plotted along the x axis, and the low-angle light 
scatter (2° to 3°) is plotted along the y axis. (Figure 2). 
The RBC map shows the relationship between the light-scatter measurements and the cell-
by-cell characteristics of volume and hemoglobin concentration. The map grid encompasses 
RBC volumes between 30 fL and 180 fL and hemoglobin concentrations between 190 g/L 
and 490 g/L. (Figure 3). 
The measurement of %Hypo (defined as the percentage of red blood cells with Hb 
concentration less than 280 g/L) is a sensitive method for quantifying the hemoglobinization 
of mature red cells. Because of the long circulating life span of mature erythrocytes %Hypo 
values are related to iron status in the last 2-3 months, and have been recognised as an 
indicator of iron deficiency (Macdougal 1998; Bovy et al., 2005; Bovy et al., 2007). %Hypo < 
5% is considered normal. Two different criteria, more specifically, %Hypo >5% and >10% 
have been used. %Hypo >10% has been more commonly used for defining absolute iron 
deficiency and functional iron deficiency (Locatelli et al., 2004). 
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Fig. 3. Volume/Hemoglobin Concentration (V/HC) cytogram (Mie Map) is a linear version 
of the RBC scatter cytogram. Hemoglobin concentration is plotted along the x axis and cell 
volume is plotted along the y axis. Only red blood cells appear on this cytogram. 
Markers organize the cytogram into 9 distinct areas of red blood cell morphology. 
On the x axis, hemoglobin concentration markers are set at 280 g/L (3) and 410 g/L (4). 
Red blood cells with a hemoglobin concentration less than 280 g/L are hypochromic, while 
cells with a hemoglobin concentration greater than 410 g/L are hyperchromic. 
On the y axis, RBC volume markers are set at 60 fL (1) and 120 fL (2). 
Red blood cells with a volume less than 60 fL are microcytic, while cells with a volume 
greater than 120 fL are macrocytic. 
CHr and %Hypo have been used as a diagnostic tool, together with biochemical markers, to 
distinguish IDA from ACD, and are incorporated to the guidelines for the monitoring of 
recombinant human erythropoietin rHuEpo therapy (Macdougall et al., 2000; Kotisaari 2002; 
Locateli et al., 2004). 
1.3.2 Sysmex 
Sysmex XE analyzers (Sysmex Corporation, Kobe, Japan) employ flow cytometry 
technology. In the reticulocyte channel blood cells are stained by a polymethine dye, specific 
for RNA/DNA, and analysed by flow cytometry using a semiconductor laser. A bi-
dimensional distribution of forward scattered light and fluorescence is presented as a 
scattergram, indicating mature red cells and reticulocytes (Figure 4). 
Forward scatter correlates with erythrocyte and reticulocyte hemoglobin content (Ret He, 
RBC He). 
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Ret He is the mean value of the forward light scatter histogram within the reticulocyte 
population obtained in a reticulocyte channel on the Sysmex XE-2100 hematology analyzer. 
Measurements of Ret He provides useful information in diagnosing anemia, iron restricted 
erythropoiesis and functional iron deficiency and response to iron therapy during r-HuEpo 
(Buttarello et al, 2004; Canals et al, 2005; Brugnara et al, 2006; Thomas et al, 2006; Garzia et al., 
2007).  
Ret He, generated by all Sysmex XE analysers (Sysmex Corporation, Kobe, Japan), has been 
recognised as a direct assessment of the incorporation of iron into erythrocyte hemoglobin 
and a direct estimate of the recent functional availability of iron into the erythron, thus 
provides the same information as CHr (Thomas et al., 2005; David et al., 2006). Twenty nine 
pg is the cut off value that defines deficient erythropoiesis Several studies have 
demonstrated that Ret He and CHr have the same clinical meaning (Mast et al, 2008; Maconi 
et al., 2009; Miwa et al., 2010).  
 
Fig. 4. In the reticulocyte channel blood cells are stained by a polymethine dye, specific for 
RNA/DNA, and analysed by flow cytometry using a semiconductor laser. A bi-dimensional 
distribution of forward scattered light and fluorescence is presented as a scattergram, 
indicating mature red cells and reticulocytes. Forward scatter correlates with erythrocyte 
and reticulocyte hemoglobin content (RBC He, Ret He). 
The Sysmex XE 5000 analyzer incorporates flow fluorescence cytometry technology, which 
enables independent measurement of the volume and hemoglobin content of individual red 
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cells. Derived from this technology four new RBC extended parameters or erythrocyte 
subsets are now available in this analyzer. 
%Hypo-He indicates the percentage of hypochromic red cells with a Hb content < 17 pg. 
%Hyper-He indicates the percentage of hyperchromic red cells with a Hb content > 49 pg. 
%Micro R indicates the percentage of microcytic red cells with a volume less than 60 fL. 
%Macro R indicates the percentage of macrocytic red cells with a volume greater than 120 fL. 
The new Symex XE 5000 analyzer reports the percentages of hypochromic red cells; the 
reference range and the values in different types of anemia have been published (Urrechaga 
et al., 2009). 
%Hypo-He indicates the percentage of hypochromic red cells with an Hb content equivalent 
to less than 17pg. Recent studies confirm the clinical reliability of the hypochromic red cells, 
reported by the Sysmex XE 5000 counter, as markers of iron deficiency in hemodialysis 
patients; 2.7 % is the cut off value which defines iron deficiency (Buttarello et al., 2010).  
Figure 5 shows s a scattergram of the reticulocyte channel. 
 
 
Fig. 5. A bi-dimensional distribution of forward scattered light and fluorescence is presented 
as a scattergram, indicating mature red cells and reticulocytes. Forward scatter correlates 
with the hemoglobin content. A new algorithm divides the RBC He signal in three areas. 
The percentages of red cells subsets can be calculated and the new parameters %Hypo-He 
and %Hyper-He obtained. 
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%Hypo-He indicates the percentage of hypochromic red cells with a Hb content < 17 pg. 
%Hyper-He indicates the percentage of hyperchromic red cells with a Hb content > 49 pg. 
1.3.3 Beckman-Coulter 
The percentage of hypochromic red cells are only available on Siemens analyzers (Siemens 
Medical Solutions Diagnostics, Tarrytown N.Y., USA) and on the new Sysmex analyzer XE 
5000 (Sysmex Corporation, Kobe, Japan); this fact limits its generalized use. Beckman 
Coulter (Beckman Coulter Inc. Miami, Fl, USA) applies the Volume Conductivity Scatter 
technology to this field and new parameters are now available on the LH series analyzers. 
Low hemoglobin density (LHD %) derives from the traditional mean cell hemoglobin 
concentration (MCHC), using the mathematical sigmoid transformation 
  LHD % 100 1 1 1 e 1.8 30 MCHC        
MCHC is an all inclusive measure of both the availability of iron over the preceding 90–120 
days, and of the proper introduction of iron into intracellular hemoglobin. In the same way 
LHD% is related to iron availability and the hemoglobin concentration of the mature red 
cells. In this equation defining LHD %, in addition to the standard sigmoid function, a 
square root is applied to further enhance numerical resolution in the region corresponding 
to the lower end, to improve the differentiation between the normal and the abnormal 
among the blood samples having relatively low values of LHD %.  
The reference range for LHD % and the values in normal population and different types of 
anemia have been established (Urrechaga, 2010). Then a study was conducted to investigate 
its clinical usefulness in the assessment of iron status in terms of correlation with %Hypo 
(Urrechaga et al., 2010) and sTfR (Urrechaga et al., 2011). 
Cells are identified and classified by simultaneous three-dimensional analysis using 
Volume, Conductivity, and Light Scatter (Figure 6). Volume, as measured by direct current, 
is used to identify the size of the cell. Conductivity, or radio frequency measurements, 
provides information about the internal characteristics of the cell. Light scatter 
measurements, obtained as cells pass through the helium-neon laser beam, provide 
information about cell surface characteristics and cell granularity. 
2. Materials and methods  
2.1 Criteria for selecting the groups of patients 
Samples from 120 healthy individuals, 72 iron deficiency anemia (IDA), 60 IDA with acute 
phase response (IDA APR), 71 chronic kidney disease (CKD) and 58 anemia of chronic 
disease (ACD) were randomly extracted from the routine workload and run sequentially on 
both LH 750 (Beckman Coulter Inc. Miami, Fl, USA) and Advia 2120 (Siemens Medical 
Solutions Diagnostics, Tarrytown N.Y., USA) analyzers within 6 hours of collection. 
Healthy group: 54 male and 66 female adult subjects, with no clinical symptoms of disease 
and with results of the complete blood count and biochemical iron metabolism markers 
within reference ranges.  
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LEU
PLQ
RET
ERIT
 
Fig. 6. the Beckman -Coulter cube in which the cells are classified according to the volume, 
conductivity and laser scatter signals. ERIT , erythrocytes; PLQ, platelets; RET, reticulocytes; 
LEU, leucocytes. 
A group of 132 IDA patients fulfilled traditional diagnostic criteria for iron deficiency 
anemia diagnosis, serum iron < 7.5 μmol/L, transferrin saturation < 20 %, ferritin < 50 µg/L, 
and Hb < 110 g/L (Cook, 2005), were included before iron treatment. This group was 
divided into a non acute phase response group (n=72, CRP < 5 mg/L) and acute phase 
response group (n=60, CRP > 5 mg/L). Acute phase response included inflammation or 
infectious conditions, in addition to ferropenic status. 
CKD patients were managed according to the recommendations of the NKF-K/DOQI 
guidelines (Locatelli et al., 2004). All patients were treated with a variety of erythropoietin 
doses, the majority of them were treated with a maintenance dose of intravenous iron 
weekly, in order to maintain Hb at the recommended level 110 - 120 g/L. 
ACD group included patients with a variety of diseases: chronic infections (tuberculosis); 
neoplasic disorders (Hodgkin‘s disease, breast carcinoma); non infectious inflammatory 
diseases (rheumatoid arthritis, systemic lupus erythematosus). ACD patients received 
treatment to maintain normal erythropoiesis and presented the traditional diagnostic 
criteria for ‘Functional iron-deficiency’ diagnosis Transferrin saturation < 20%, Hb < 110 
g/L and serum ferritin values normal or over the reference range (Weiss & Goodnough, 
2005). 
In a second phase of the study ACD group was extended to 85 patients. This group was 
further subdivided based on sTfR levels. ACD patients with sTfR higher than 21 nmol/L 
were considered to have storage iron depletion (iron deficiency associated, n=24) and 
patients with normal sTfR were considered to have functional iron deficiency (n=61). 
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sTfR was measured with Access sTfR assay in the Access immunochemical analyzer 
(Beckman Coulter Inc., Miami Fl, USA). 
2.2 Statistical evaluation of analytical results 
Statistical software package SPSS (SPSS; Chicago, IL, USA) version 17.0 for Windows was 
applied for statistical analysis of the results. 
Reference ranges were calculated from the results obtained in the group of healthy subjects 
(95 central percentiles of the distribution). Kolmogorov – Smirnoff test was applied to verify 
the Gaussian distribution of LHD% values. 
When the parameters under study presented a non Gaussian distribution non parametric 
tests were applied. Correlation coefficients were calculated by Spearman method; 
independent samples Mann-Whitney U test was performed; p values less than 0.05 were 
considered to be statistically significant. 
Receiver operating characteristic (ROC) curve analysis was utilized to illustrate the 
diagnostic performance of LHD% and other Laboratory tests in the detection of iron 
deficiency status; two analysis were performed; first iron deficiency was defined by %Hypo 
> 5 %, and second , including 85 ACD patients, the gold standard was sTfR > 21 nmol/L. 
Cut off values were established based on the optimal combination of sensitivity and 
specificity. 
Cohen’s Kappa Index of Inter-rater Reliability (κ index) was calculated to determine the 
concordance between LHD% and sTrR. 
κ has a range from 0-1.0, the larger values indicate better reliability; κ > 0.7 is considered 
satisfactory. 
 
 RBC 
1012/L 
Hb 
g/L 
MCV 
fL 
MCH pg MCHC 
g/L 
Iron 
µmol/L 
Transf 
g/L 
Ferritin 
µg/L 
 Sat 
 % 
          
Health
 
4.9 
(0.27) 
154 
(6.4) 
91.1 
(2.55) 
31.3 
(1.53) 
343 
(5.2) 
16.5 
(0.62) 
2.53 
(0.2) 
75 
(2.8) 
31 
(1.9) 
IDA 
 
4.6 
(0.61) 
95 
(14.2) 
70 
(10.3) 
22.5 
(4.23) 
320 
(17.3) 
4.8 
(2.15) 
3.31 
(0.53) 
14 
(9) 
6 
(3.6) 
IDA 
APR 
4.4 
(0.43) 
96 
(12.1) 
75.8 
(3.7) 
21.5 
(1.3) 
327 
(9.2) 
5.1 
(3.5) 
2.78 
(0.28) 
37 
(25) 
9 
(5.6) 
ACD 3.5 
(0.48) 
101 
(11) 
93.2 
(6.0) 
31.9 
(2.23) 
343 
(10) 
10.0 
(6.8) 
2.68 
(0.66) 
522 
(704) 
15 
(5) 
CKD 3.5 
(0.45) 
112 
(8.5) 
95.6 
(6.67) 
31.1 
(2.23) 
325 
(8) 
9.8 
(4.47) 
1.87 
(0.43) 
335 
(204) 
21 
(10) 
Table 1. shows the hematological and biochemical data, mean and (standard deviation), of 
the different groups. 120 healthy individuals, 72 iron deficiency anemia (IDA), 60 IDA with 
acute phase response (IDA APR), 71 chronic kidney disease (CKD) and 58 anemia of chronic 
disease (ACD). 
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RBC, red blood cells; Hb, hemoglobin; MCV, mean cell volume; MCH, mean cell 
hemoglobin; MCHC, mean cell hemoglobin concentration; Transf, transferrin; Sat, % 
transferrin saturation.  
3. Results 
Table 1 shows the hematological and biochemical data, mean and (standard deviation). The 
parameters presented are of general use for every Laboratory in the evaluation of anemia. 
The patients included in the study sufferered common clinical situations in our daily 
practice: anemia of chronic disease (ACD), chronic kidney disease (CKD), iron deficiency 
anemia (IDA) iron deficiency anemia and acute phase response (IDA APR)  
The healthy group was recruited to assess the reference range for the new parameter LHD 
%. 
LHD % values in a population of 120 healthy adult subjects were not normally distributed 
and showed a non Gaussian distribution (Kolmogorov-Smirnoff test, p=0.034; figure 7). 
Reference range 0 - 4.4 %. 
 
Fig. 7. Low hemoglobin density (LHD %) values in a population of 120 healthy adult subjects. 
The values showed a non Gaussian distribution (Kolmogorov-Smirnoff test, p=0.034).  
Table 2 exhibits %Hypo values, mean and standard deviation (SD) and LHD % values, 
median and 5th - 95th interquartiles (IQ), in the variety of anemias and healthy subjects 
included in the study. 
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 % Hypo 
Mean (SD) 
 LHD % 
Median (IQ) 
Healthy 0.13 (0.15) 2.1 (0.9-4.1) 
IDA 17.2 (17.4) 29.6 (7.5-76) 
IDA APR 16.8 (15.5) 27.3 (8.3-71.2) 
ACD 4.1 (4.4) 7.3 (5.1-30) 
CKD 5.1 (6.7) 9.6 (5.6-27) 
Table 2. %Hypo values, mean and standard deviation (SD) and LHD % values, median and 5th 
- 95th interquartiles (IQ), in the variety of anemias and healthy subjects included in the study. 
IDA, iron deficiency anemia; IDA APR, iron deficiency anemia and acute phase response; 
ACD, anemia of chronic disease; CKD, chronic kidney disease. 
Correlation between %Hypo and LHD% values, r = 0.869 (Spearman method) (p<0.001). y = 
1.338 x + 4.40 (Figure 8). 
Independent samples U test was performed in order to detect statistical deviations between 
the groups of patients. 
Significant differences in LHD % values (p<0.001) were detected when groups with iron 
deficiency (IDA, median 29.6 % and IDA with APR, median 27.3 %) were compared with 
patients undergoing therapy (ACD, median 7.3 %; CKD, median 9.6 %) and the healthy 
subjects (median 2.1 %). 
 
Fig. 8. Relationship between %Hypo and LHD% values (Spearman correlation) r = 0.869  
y = 1.338 x + 4.4. 
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No statistic difference was found between IDA group and IDA patients with acute phase 
response (p=0.578). 
Receiver operating characteristic (ROC) curve analysis for LHD% in the diagnosis of iron 
deficiency, defined by %Hypo > 5% AUC 0.954, cut off 6.0 %, sensitivity 96.6%, specificity 
83.3% (Figure 9). 
Discriminant efficiency of biochemical parameters and classical erythrocyte indices: mean 
cell hemoglobin (MCH), AUC 0.89; mean cell volume, (MCV), AUC 0.822; serum ferritin, 
AUC 0.722; serum iron, AUC 0.683 (Figure 9). 
In the group including 85 ACD patients, significant differences were detected when iron 
replete ACD patients (LHD% 10.5 %) were compared to the group with both ACD and IDA 
(LHD% 24.1 %, p<0.0001). 
Table 3 exhibits sTfR values, mean and standard deviation (SD) and LHD % values, median 
and 5th - 95th interquartiles in these patients. 
ROC analysis for LHD% in the detection of iron deficiency rendered area under curve 
(AUC) 0.903; at a threshold value 5.5 % sensitivity was 88.6 % and specificity 76.9 %. The 
ferropenic state was defined by a sTfR > 21 nmol/L. 
Using the cut off 5.5 % for LHD% the k index obtained in comparison to sTfR was 0.65. 
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Fig. 9. Receiver operating characteristic (ROC) curve analysis for LHD% and Biochemical 
parameters and classical erythrocyte indices in the diagnosis of iron deficiency, defined by 
%Hypo >5%. LHD% Ares under curve (AUC) 0.954; mean cell hemoglobin (MCH), AUC 
0.89; mean cell volume, (MCV), AUC 0.822; serum ferritin, AUC 0.722; serum iron, AUC 
0.683. 
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 Healthy 
 
ACD ACD/ IDA 
 
ACD/ 
Iron replete 
LHD% 2.1 14.2 24.1 10.5 
 (0.9-4.1) (4.5-68.9) (5.1-68.9) (4.5-14.0) 
sTfR (nmol/L) 15.1 
 (2) 
20.3  
(6.6) 
30.8  
(8.3) 
17.9  
(6.1) 
Table 3. sTfR values, mean and standard deviation (SD) and LHD % values, median and 5th - 
95th interquartiles in a group of 120 healthy subjects, 85 anemia of chronic disease patients 
(ACD), 61 of them iron replete and 24 iron deficient (ACD/IDA). 
4. Discussion 
CKD is a widespread health problem in the world and anemia is a common complication. 
Anemia conveys significant risk for cardiovascular disease, faster progression of renal 
failure and decreased quality of life. 
Ferrokinetic studies provided on last decades important insights into human iron 
homeostasis in vivo. More recently, modern molecular biology and genetic studies of model 
organisms have extended our knowledge of normal iron biology and led to the 
identification of new key players in iron homeostasis and the detailed understanding of 
human iron disorders.  
New insights in iron metabolism and the understanding of iron homeostasis, erythropoietin 
production and regulation and the relationships between mediators of inflammation and 
bone marrow erythropoiesis are modifying the traditional view on anemia, in special 
anemia of chronic disease. The anemia of CKD is among them, with the added burden of 
erythropoietin deficiency. Recent elucidations of specifically disrupted points of erythroid 
marrow function by inflammatory mediators, especially proinflammatory cytokines and 
inflammation-mediated induction of hepcidin, have improved our understanding of 
erythropoiesis-stimulating agents (ESAs) hyporesponsiveness.  
These patients require a thorough evaluation to identify and correct causes of anemia other 
than erythropoietin deficiency. The mainstay of treatment of anemia secondary to CKD has 
become ESAs. The use of ESAs does carry risks and these agents need to be used 
judiciously. Iron deficiency often co-exists in this population and must be evaluated and 
treated. Correction of iron deficiency can improve anemia and reduce ESA requirements. 
Partial, but not complete, correction of anemia is associated with improved outcomes in 
patients with CKD. 
Undoubtedly, the advent of ESA and various intravenous iron preparations has resulted 
in a much more effective management of anemia of CKD, allowing clinicians to maintain 
hemoglobin levels in certain desired ranges and to effectively treat iron deficiency. 
Among the emerging challenges are the risks associated with administering high ESA and 
iron doses, leading to elevated hemoglobin levels and iron overload. Goal-oriented 
treatment strategies targeting “desirable” hemoglobin and iron levels are now the norm in 
clinical nephrology. 
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The treatment of renal anemia with rHuEpo has improved the quality of life and outcome of 
hemodialysis patients. The efficacy of this therapy depends on the identification and 
correction of resistance factors, such as vitamin deficiency, inflammation, 
hyperparathyroidism. The major cause of resistance to rHuEpo is iron deficiency. The 
assessment of functional iron deficiency remains a daily challenge for nephrologists and 
their need to be careful of an appropriate use of the resources and the need to optimize 
patient treatment. 
A better understanding of iron homeostasis enhance treatments for anemia. Subsequently, 
evidence-based diagnostic strategies must be developed, using both conventional and 
innovative laboratory tests, to differentiate between the various causes of distortions of iron 
metabolism.  
Efforts have been made to evaluate some readily available and relatively inexpensive 
laboratory parameters as indirect markers of iron restricted erythropoiesis and iron 
availability in a clinical context influenced by inflammation and acute phase reaction.  
The assessment of iron requirements and monitoring of therapy require accurate markers. It 
is desirable to seek alternative markers for iron status widely available. LHD% is related to 
iron availability for erythropoiesis in the previous weeks, derived from MCHC, it could be 
calculated in different hematological counters. 
The data exposed show the reliability of LHD% in distinguishing iron deficient patients 
with and without inflammation. This parameter could help to the correct classification of 
patients with iron deficiency when the traditional markers become unreliable: it is 
particularly challenging the accurate assessment of iron status in chronically ill patients such 
as CKD. 
LHD % correlates with the percentage of hypochromic erythrocytes as reported by Siemens 
analyzers (%Hypo) and comparing the results obtained for LHD% with those of sTfR the 
reliability of LHD% in distinguishing iron deficient patients with and without inflammation 
has been stated. 
In conclusion, these results show that the new LHD% parameter is useful for diagnosing 
iron deficiency and a reliable parameter recognizing subsets of patients and therefore 
improving the diagnosis and management of anemia.The analysis of LHD% can be 
performed simultaneously in the course of routine blood counts, with no incremental 
costs and no additional needs of more blood sampling. In conjunction with standard 
blood cell counts and iron parameters could enable the diagnosis to be made rapid and 
accurately.  
More prospective and longitudinal studies are needed in order to verify the results 
obtained, to determine their reliability for clinical purposes or whether the additional 
information provided could be used in managing the iron requirements of patients in 
different clinical situations. 
5. Conclusion 
Iron metabolism is a dynamic process which cannot be defined by one laboratory test only. 
The analysis of these new parameters can be performed simultaneously in the course of 
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routine blood counts, with no incremental costs and no additional needs of more blood 
sampling. In conjunction with standard blood cell counts and iron parameters could enable 
the diagnosis to be made rapid and accurately.  
Prospective and longitudinal studies are needed in order to verify the published results, to 
determine their reliability for clinical purposes or whether the additional information 
provided could be used in managing the iron requirements of patients, allowing better 
evaluation of the causes underlying apparently similar conditions of anemia and improving 
the collaboration between laboratory professionals and clinicians. 
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